225
Participants
Start Date
January 25, 2019
Primary Completion Date
September 1, 2023
Study Completion Date
September 1, 2023
3BNC117-LS-J
300mg
10-1074-LS-J
300mg
Combination 3BNC117-LS-J and 10-1074-LS-J
30mg/kg of each
Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1
Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2
Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3
Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
Placebo
0.9% Saline
Placebo
Buffer Solution
The Rockefeller University, New York
Fred Hutchinson Cancer Research Center, Seattle
Brigham and Women's Hospital, Boston
Partners in Health Research and Development, Thika
Kenya AIDS Vaccine Initiative - Institute of Clinical Research, Nairobi
Center for Family Health Research, Kigali
Wits Reproductive Health and HIV Institute, Johannesburg
Uganda Virus Research Institute, Entebbe
Infectious Diseases Institute Kasangati, Kampala
Fred Hutchinson Cancer Center
OTHER
Rockefeller University
OTHER
Brigham and Women's Hospital
OTHER
International AIDS Vaccine Initiative
NETWORK